Sulfatinib for bone cancer that has come back
Treatments studied
Part of Cancer clinical trials.
This trial tests a pill called sulfatinib for young people with bone cancer (osteosarcoma) that has come back or not responded to standard treatments. Sulfatinib works by cutting off the blood supply that tumors need to grow, and the goal is to see if it can control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have osteosarcoma (a type of bone cancer) that has come back or not responded to standard treatments.
- You must be between 2 and 25 years old.
- Your cancer must be visible on an imaging scan (like a CT or MRI).
- Your heart, liver, kidneys, and blood counts must be in a certain range to be safe.
- You must not have an active infection, and you cannot be pregnant or breastfeeding.
- You cannot have had too many prior treatments that target blood vessel growth, and you cannot have taken this exact drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
This trial tests a combination of two drugs, losartan and sunitinib, in people with osteosarcoma that has come back or spread after prior treatment. The study aims to see if this combination is safe and effective.
This trial tests a new drug called vactosertib for people with a type of bone cancer called osteosarcoma that has come back or hasn't responded to other treatments. The goal is to see if the drug can help shrink or slow the cancer and to check its safety.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.